Specify a stock or a cryptocurrency in the search bar to get a summary
Suzhou Basecare Medical Corporation Limited
2170Suzhou Basecare Medical Corporation Limited, an investment holding company provides genetic testing solutions for assisted human reproduction in the People's Republic of China and Australia. The company offers genetic test kit products, which include pre-implantation genetic test kits, such as PGT-A to detect aneuploidy; PGT-M to detect single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kits to detect chromosome structural rearrangements, which are common causes of recurrent miscarriage. It also offers liquid nitrogen storage dewar, Cryopreservation system, and sperm quality analyzer; universal kits for sequencing effects; sample preservation solution; and nucleic acid purification and DNA extraction kits. The company also engages in the research, development, manufacture, and sale of testing kits, testing devices, and instruments. In addition, it provides marketing services; and engages in the research and development of software for testing devices and instruments. The company serves hospitals and reproductive clinics. Suzhou Basecare Medical Corporation Limited was incorporated in 2010 and is headquartered in Suzhou, China. Address: Building A3 BioBay, Suzhou, China
Analytics
WallStreet Target Price
79.31 HKDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 2170
Dividend Analytics 2170
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 2170
Stock Valuation 2170
Financials 2170
Results | 2019 | Dynamics |